AJG Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
AJG is not a clear buy right now for a beginner long-term investor with $50,000-$100,000 who is unwilling to wait for a better entry. The business quality is strong and Wall Street still leans constructive, but the stock is trading near short-term resistance while momentum is overbought, so the current setup favors holding rather than buying aggressively today.
AJG is in an upward price trend, supported by a positively expanding MACD histogram (3.178 above 0). However, RSI_6 is extremely overbought at 89.888, which signals the recent rally has already run hot. Price at 250.05 is just below R1 at 245.902? Correction: the provided levels place price above R1 and approaching R2 at 256.494, meaning the stock is extended and closer to resistance than support. Moving averages are converging, suggesting the move is mature rather than freshly starting. The short-term pattern data also implies only modest upside over the next month.
Congress trading data is also net positive, with 4 purchase transactions versus 3 sales and purchases occurring in meaningful size, suggesting influential investors have been accumulating. The company remains a high-quality insurance broker with execution and growth options still appreciated by the market.
There has been no news in the recent week, so there is no fresh catalyst driving a new entry. Hedge funds are reported as selling heavily, with selling up 5037.71% over the last quarter, which is a notable negative sentiment signal. Analyst targets have also shown some downward revisions from a few firms, and Keefe Bruyette’s latest view is only Market Perform. The stock is technically overbought, so near-term upside may be limited.
No latest-quarter financial statement detail was provided because the financial snapshot returned an error. Based on the analyst notes, the company did report an adjusted Q1 EPS beat and maintained 2026 guidance, with organic growth described as in-line and Q2 organic growth outlook at 5%. The latest quarter referenced in the analyst notes is Q1, and the growth trend appears stable rather than accelerating sharply.
Analyst sentiment is mixed but still broadly positive. Positive views: Evercore ISI remains Outperform with a $295 target, Mizuho is Outperform with a $261 target, Citi upgraded to Buy with a $250 target, and Morgan Stanley remains Overweight with a $265 target. Neutral/hold views: Keefe Bruyette is Market Perform at $242, Truist is Hold at $225, and Piper Sandler is Neutral at $211. The trend suggests Wall Street likes the company’s quality and growth but sees valuation pressure and slowing P&C pricing tailwinds limiting upside at current levels.
